Liquidia Corp (LQDA) company profile
Close on Nov 17, 2026Market cap $5.08BP/E 40.8Yield –
About Liquidia
Pharmaceutical Preparations, SIC 2834
Liquidia is a biopharmaceutical company that develops, manufactures, and commercializes treatments for patients with severe respiratory and vascular diseases, focusing on pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The company’s primary offerings include Yutrepia, an inhaled dry-powder treprostinil therapy, and a generic treprostinil injection marketed in partnership with Sandoz. Liquidia promotes its products to healthcare professionals, notably pulmonologists and cardiologists, as well as specialty pharmacies and medical distributors.
The company operates primarily within the United States, where it maintains a targeted commercial sales force calling on specialized medical centers. Liquidia conducts manufacturing and research operations at a 45,000-square-foot facility in Morrisville, North Carolina, and holds a lease for an additional 70,131-square-foot site in Morrisville. Globally, the company conducts clinical trials across more than 100 sites in at least 20 countries.
Summary of the business section of Liquidia's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Liquidia Corp
- Founded
- 2004
- Headquarters
- Morrisville, NC
- Address
- 419 Davis Drive, Suite 100 27560
- Phone
- (919) 328-4400
- Website
- www.liquidia.com
- Employees
- 216, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Raleigh, North Carolina
Stock & identifiers
- Ticker
- LQDA
- Exchange
- Nasdaq
- IPO date
- Jul 26, 2018
- Shares outstanding
- 90M, Jul 29, 2026
- Public float
- $847.01M, Jun 30, 2025
- Filer category
- Non-accelerated filer
- SEC CIK
- 1819576
- CUSIP
- 53635D202
- ISIN
- US53635D2027
- FIGI
- BBG001J2P905
- Share class FIGI
- BBG001V0GFD7
- LEI
- 549300O826O5VQJTG707
- EIN
- 85-1710962
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Roger Jeffs | Chief Executive Officer, Director | 2,167,515 |
| Jason Adair | Chief Business Officer | 177,269 |
| Dana Boyle | Chief Accounting Officer | 164,028 |
| Russell Schundler | General Counsel | 617,341 |
| Rajeev Saggar | Chief Medical Officer | 141,467 |
| Michael Kaseta | CFO and COO | 340,148 |
| Sanjeev Khindri | Chief Development Officer | 64,846 |
| Sarah Krepp | Chief Human Resource Officer | 115,241 |
| Scott Moomaw | Chief Commercial Officer | 181,487 |
| Stephen M. Bloch | Director | 104,570 |
| Raman Singh | Director | 53,105 |
| Katherine Rielly-Gauvin | Director | 56,364 |
| Arthur S. Kirsch | Director | 46,637 |
| Paul B. Manning | Director | 673,878 |
| Partners LP Caligan | Director | 8,163,229 |
| Joanna Horobin | Director | 39,637 |
| Damian deGoa | Director | 92,353 |
| David Edward Johnson | Director | 8,157,347 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $7.71M | $34.95M | $2.81M | $708 | $121 |
| FY2024 | $6.75M | $6.24M | $3.32M | $241 | $91 |
| FY2023 | $4.89M | $15.46M | $2.24M | $247 | $92 |
| FY2022 | $10.76M | $13.89M | $1.76M | $131 | $89 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Roger A. Jeffs Chief Executive Officer | $824.00K | $25.00K | $5.59M | $1.25M | $18.34K | $7.71M | +14% |
| Michael Kaseta Chief Financial Officer and Chief Operating Officer (4) | $592.25K | $25.00K | $2.75M | $772.80K | $16.02K | $4.16M | +10% |
| Russell Schundler General Counsel and Secretary | $540.75K | $25.00K | $2.50M | $588.00K | $17.35K | $3.67M | +28% |
| Rajeev Saggar Chief Medical Officer | $539.35K | $25.00K | $1.75M | $586.48K | $16.02K | $2.92M | +36% |
| Scott Moomaw Chief Commercial Officer | $449.90K | $25.00K | $1.70M | $489.22K | $16.84K | $2.68M | +45% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we employed 216 employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Aug 5, 2020 | Merger | Registration of securities for a merger or exchange offer (S-4) |
See a number that looks wrong?